The RAPID coverage pathway aims to reduce delays between FDA authorization and Medicare coverage for breakthrough technologies.
RT’s Three Key Takeaways:
- Accelerated Coverage Timeline: The new RAPID pathway could enable Medicare national coverage and payment as soon as two months after market authorization, significantly reducing the previous timeline of a year or more.
- Early Agency Alignment: Centers for Medicare & Medicaid Services (CMS) will engage with the Food and Drug Administration (FDA) and manufacturers earlier in the development cycle to ensure clinical trial data meet both regulatory and coverage requirements.
- Eligibility Requirements: To qualify for the pathway, devices must be designated as breakthrough technologies, address unmet needs in the Medicare population, and be part of a study that includes Medicare beneficiaries and specific clinical health outcomes.
The Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA) announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway to expedite access to specific breakthrough medical devices for Medicare beneficiaries, according to a news release. This initiative aims to align regulatory and coverage expectations in advance to reduce delays between FDA market authorization and Medicare national coverage determinations.
The RAPID coverage pathway allows CMS and the FDA to work together with innovators earlier in the technology development lifecycle. This coordination ensures that evidence generated for FDA review can also support Medicare coverage decisions, which has historically been a point of delay for new healthcare technologies.
“FDA and CMS each play a critical role in getting new medical devices to patients, and they work most effectively when aligned sooner in that process,” said Mehmet Oz, CMS administrator.
Marty Makary, FDA commissioner, added that the agencies are functioning as a single team to deliver life-saving devices to patients as soon as they are proven to work.
Through the RAPID pathway, CMS will participate in early and frequent engagement between the FDA and device manufacturers. This allows manufacturers to link with CMS experts early in development to understand which clinical outcomes are most relevant for Medicare beneficiaries. The pathway is available for certain Class II devices participating in the FDA Total Product Life Cycle Advisory Program (TAP) and Class III devices regardless of TAP participation.
To be eligible for the RAPID pathway, devices must be the subject of an Investigational Device Exemption (IDE) study that enrolls Medicare beneficiaries and evaluates clinical health outcomes agreed upon by both the FDA and CMS. This approach allows the agencies to rely on premarket evidence to inform both the regulatory review and coverage processes, reducing duplication and increasing transparency for innovators.
Under this streamlined process, CMS will issue a proposed National Coverage Determination (NCD) the same day an eligible device receives FDA market authorization. This triggers a statutorily required 30-day public comment period. CMS officials stated that this approach could enable predictable Medicare national coverage and payment as soon as two months after market authorization, compared to approximately a year or more under the current system.
As CMS focuses on the implementation of the RAPID pathway, the Transitional Coverage for Emerging Technologies (TCET) pathway will be paused for new candidates. A proposed procedural notice outlining the RAPID pathway will be published in the Federal Register, followed by a 60-day public comment period. The effective date of the new pathway is expected to occur upon the publication of the final notice.
